Concorde Clinical Trials
Trials actively enrolling patients:
- NEW Hepatitis C Trial The Liver Disease Division of Concorde Medical is very excited to announce that we are participating in a ground breaking trial of two new drugs for the treatment of hepatitis C. These medications from Pharmasset Corporation have been shown in preliminary trials to be the most effective medications yet developed for the cure of hepatitis C. These are also the first direct acting anti viral drugs that appear to be effective in genotypes 4 5, and 6 as well as the most common genotype 1. If you have hepatitis C, have never been treated and are over 18 you may qualify for the study. The medications will be given at no cost to the patient. The number of spots available is limited.
- Hepatitis C. Concorde Medical Group is now enrolling patients in a Gilead Sciences Phase IIb Hepatitis C clinicial trial for patients that are Genotype 1 that have never been treated. If you are eligible for the trial you may be able to receive 2 new oral direct anti-viral agents in addition to the standard peginterferon and ribavirin. These medications have been shown to substantially improve cure rates for Hepatitis C. Participants will receive treatment medication at no cost and be monitored closely by our study physicians. Patients will also receive compensation at the end of the study. We are proud to have been selected to participate in this trial for a potentially improved treatement for Hepatitis C Genotype 1.When inquiring, please leave your contact information as we are in the process of acquiring several new clincal trials that involve the treatment of Hepatitis C. If you are not eligible for one, there will be others for which you may be eligible to participate.
- Chronic Pancreatitis Trial. This is a Phase II randomized placebo-controlled trial to investigate the safety and efficacy of a single administration of Tanezumab 20mg sc in patients with chronic pain secondary to chronic pancreatitis. Patients will be randomized to Tanezumab 20mg sc versus placebo in a 1:1 ratio. The efficacy of a single dose of Tanezumab versus placebo will be monitored for 8 weeks; the safety of Tanezumab will be assessed over 16 weeks. Including the screening period, the study will last a total of 20 weeks.
- Irritable Bowel Syndrome-Diarrhea Predominant sponsored by Salix Pharmaceuticals. This is a Phase 2, randomized, placebo- controlled 12 week study to assess the efficacy and safety of mesalamine daily for the treatment of IBS-D. Patients will be randomized to one of 3 arms: 2 capsules (750mg) of mesalamine daily, 4 capsules (1500mg) of mesalamine daily or 4 placebo capsules daily for 12 weeks. Patients will come in for a total of 6 study visits. If patients have not had colonoscopy within the past 5 years, one will be provided by the sponsor.
- Irritable Bowel Syndrome-Diarrhea Predominant - sponsored by Furiex Pharmaceuticals. This is a Phase 2, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of JNJ-27018966, which is a locally active mixed mu-opioid receptor agonist/delta-opioid receptor antagonist for IBS- D. It is an 18 week study encompassing 8 study visits. Patients will be randomized 80:20 to various dosages of study drug:placebo.
- Proctitis/Proctosigmoiditis - sponsored by Salix Pharmaceuticals. This is a Phase 3, randomized, double-blind placebo-controlled trial to assess the safety and efficacy of budesonide foam for patients with mild to moderate ulcerative proctitis or proctosigmoiditis. Patients will be randomized 50:50 to placebo or active treatment arm. Treatment will be given for 6 weeks for a total of 8 study visits. Patients will have 2 sigmoidoscopies - one at baseline and one at the final visit.
If you are interested in Clinical Trial participation or have any questions, please contact:
Maureen Haskins, Clinical Research Coordinator at 212-889-5544 x152 or .(JavaScript must be enabled to view this email address)
In This Section
Concorde Medical Group
232 E. 30th St.
New York, NY 10016
Telephone: (212) 889-5544
Fax: (212)
481-1089
Dr. Alex Sherman, Director of
Clinical Research
(212)889-5544 ext 165
Maureen Haskins, Certified
Clinical Research Coordinator
(212)889-5544 ext 152
or Contact Us
